US FDA nod to Teva for key specialty product to weigh on Sun Pharma

Topics US FDA | Teva Pharma | Sun Pharma

The approval to Teva Pharmaceuticals (Teva) by the US Food and Drug Administration (USFDA) for the launch of the generic version of Absorica in the US market is a negative for Sun Pharmaceutical Industries (Sun Pharma). At annual revenues in the $100-120 million range, the drug — used in treating severe acne and certain types of skin cancers — is the largest specialty product in Sun Pharma’s US portfolio.  The launch of the product and the market share that Teva could take in the coming weeks could weigh on the stock, say analysts. The patent of the product is slat.....

Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel